Form 4: Traws Pharma COO Receives Equity and Options Award

Traws Pharma's Chief Operating Officer, Nikolay Savchuk, was granted 16,419 restricted stock units and 65,676 stock options.

Summary

• Nikolay Savchuk, Chief Operating Officer and Director of Traws Pharma, Inc. (TRAW), acquired 16,419 shares of common stock through an award of restricted stock units (RSUs) on December 12, 2025.
• These 16,419 RSUs will vest 100% on the first anniversary of the grant date, converting into common stock on a one-for-one basis.
• Additionally, Mr. Savchuk was granted 65,676 stock options on December 12, 2025, with an exercise price of $2.33 per share.
• These 65,676 stock options will vest 100% on the first anniversary of the grant date, December 12, 2026, and have an expiration date of December 12, 2035.
• Following these transactions, Mr. Savchuk beneficially owns 150,606 shares of common stock directly and 65,676 stock options directly.

Sentiment

Score: 7

Explanation: The grant of significant equity and option awards to a key executive indicates strong alignment of management's long-term interests with shareholder value and confidence in the company's future prospects.

Positives

• The grant of restricted stock units and stock options to the Chief Operating Officer aligns management's long-term interests with those of shareholders, incentivizing performance.
• Equity compensation is a common method to attract and retain key executives, signaling confidence in the company's future value creation.

Future Outlook

The equity and option awards, with their one-year vesting schedule, suggest a forward-looking incentive for the Chief Operating Officer, tying a significant portion of their compensation to the company's future performance and stock appreciation.

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation due to management's aligned incentives and commitment to the company's success.

Next Steps

• Vesting of 16,419 restricted stock units on December 12, 2026.
• Vesting of 65,676 stock options on December 12, 2026.

Key Dates

Keywords

Traws Pharma, TRAW, Nikolay Savchuk, Form 4, SEC filing, stock options, restricted stock units, equity award, COO, insider transaction